BioCryst Pharmaceuticals, Inc.
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
Asset Breakdown FY2025
Total Assets: $514.2M
Liabilities Breakdown FY2025
Total Liabilities: $633.3M
Asset Breakdown
Total Assets: $514.2M
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $89.7M | 17.5% |
| Accounts Receivable | $106.8M | 20.8% |
| Inventory | $5.4M | 1.0% |
| Property, Plant & Equipment | $8.8M | 1.7% |
| Goodwill | $0 | 0.0% |
| Intangible Assets | $0 | 0.0% |
| Other Assets | $303.4M | 59.0% |
Liabilities Breakdown
Total Liabilities: $633.3M
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $15.8M | 2.5% |
| Long-Term Debt | $0 | 0.0% |
| Other Liabilities | $617.5M | 97.5% |